MEI Pharma Company Profile (NASDAQ:MSHL)

About MEI Pharma (NASDAQ:MSHL)

MEI Pharma logoMEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MSHL
  • CUSIP: N/A
  • Web: www.meipharma.com/
P/E:
  • Trailing P/E Ratio:
  • P/E Growth:
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: -13.36%
  • Return on Equity: -4.40%
  • Return on Assets: -4.09%
 
Frequently Asked Questions for MEI Pharma (NASDAQ:MSHL)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MSHL."

Who are some of MEI Pharma's key competitors?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:

  • Christine Anna White M.D., Independent Chairman of the Board
  • Daniel P. Gold Ph.D., President, Chief Executive Officer, Director
  • Thomas M. Zech, Chief Financial Officer, Secretary
  • David M. Urso, Senior Vice President of Corporate Development, General Counsel
  • Robert D. Mass M.D., Chief Medical Officer
  • Charles V. Baltic III, Independent Director
  • Kevan E. Clemens Ph.D., Independent Director
  • Nicholas R. Glover Ph.D., Independent Director
  • Thomas C. Reynolds M.D. Ph.D., Independent Director
  • William Dodge Rueckert, Independent Director

How do I buy MEI Pharma stock?

Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEI Pharma stock can currently be purchased for approximately $0.42.


MarketBeat Community Rating for MEI Pharma (NASDAQ MSHL)
Community Ranking:  2.4 out of 5 ( )
Outperform Votes:  13 (Vote Outperform)
Underperform Votes:  14 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MEI Pharma (NASDAQ:MSHL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for MEI Pharma (NASDAQ:MSHL)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for MEI Pharma (NASDAQ:MSHL)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for MEI Pharma (NASDAQ:MSHL)
Current Year EPS Consensus Estimate: $-0.2600 EPS

Dividends

Dividend History for MEI Pharma (NASDAQ:MSHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MEI Pharma (NASDAQ:MSHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for MEI Pharma (NASDAQ:MSHL)
Latest Headlines for MEI Pharma (NASDAQ:MSHL)
Source:
DateHeadline
zacks.com logoValeant's (VRX) NDA for Bowel Cleansing Drug Accepted by FDA
www.zacks.com - June 30 at 2:01 AM
bizjournals.com logoMEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma
www.bizjournals.com - May 31 at 7:00 PM
seekingalpha.com logoMEI Pharma's blood cancer candidate ME-401 performs well in early-stage study; shares up 4%
seekingalpha.com - May 31 at 7:00 PM
streetinsider.com logoMEI Pharma (MEIP) Says Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in CCL and Follicular Lymphoma
www.streetinsider.com - May 31 at 8:58 AM
reuters.com logoBRIEF-MEI Pharma Inc files for mixed shelf of up to $150 million
www.reuters.com - May 5 at 9:28 AM
finanznachrichten.de logoAcute Myeloid Leukemia (AML) Therapeutics - Global Strategic Business Report 2017 - Growing Interest in the Genetics of AML - Research and Markets
www.finanznachrichten.de - April 26 at 6:37 PM
bizjournals.com logoGlobal Acute Myeloid Leukemia (AML) Therapeutics - Pharmaceuticals
www.bizjournals.com - April 26 at 6:37 PM
bizjournals.com logoMEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer
www.bizjournals.com - April 3 at 10:05 AM
reuters.com logoBRIEF-MEI Pharma posts Q2 earnings per share $0.32
www.reuters.com - February 8 at 7:31 PM
finance.yahoo.com logoHelsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat …
finance.yahoo.com - December 5 at 10:13 AM
reuters.com logoBRIEF-MEI pharma reports fiscal year 2016 results
www.reuters.com - September 6 at 10:58 AM
seekingalpha.com logoMEI Pharma net loss improves in FY16
seekingalpha.com - September 6 at 10:58 AM
reuters.com logoCDC grants $2.4 mln to five U.S. jurisdictions to fight Zika
www.reuters.com - September 3 at 8:42 AM
reuters.com logoBRIEF-Helsinn Investment Fund reports 7.1 pct passive stake in MEI Pharma - SEC filing
www.reuters.com - August 23 at 10:41 AM
reuters.com logoBRIEF-Alphabet - Google CEO Sundar Pichai reports open market sale of Co's class A common stock and class C capital stock
www.reuters.com - August 22 at 6:16 PM
seekingalpha.com logoMEI Pharma +48% on leukemia drug deal
seekingalpha.com - August 9 at 9:29 AM
feeds.benzinga.com logo15 Biggest Mid-Day Gainers For Monday
feeds.benzinga.com - August 8 at 1:22 PM
feeds.benzinga.com logo11 Stocks Moving In Monday's Pre-Market Session
feeds.benzinga.com - August 8 at 8:49 AM
benzinga.com logoMEI Pharma's Pracinostat Gets Breakthrough Therapy Status For Its Pracinostat In Combination With Azacitidine
www.benzinga.com - August 1 at 10:56 AM
streetinsider.com logoMEI Pharma's (MEIP) Pracinostat Receives FDA Breakthrough Therapy Designation
www.streetinsider.com - August 1 at 10:56 AM
reuters.com logoBRIEF-MEI pharma's pracinostat receives FDA's breakthrough therapy designation
www.reuters.com - August 1 at 10:56 AM
finance.yahoo.com logoMEI Pharma's Pracinostat Receives Breakthrough Therapy Designation from FDA for Treatment in Combination …
finance.yahoo.com - August 1 at 10:56 AM
finance.yahoo.com logoGlobal Medulloblastoma Pipeline Review 2016 - Research and Markets
finance.yahoo.com - July 7 at 6:18 PM
finance.yahoo.com logoEssential Thrombocythemia - Pipeline Review, H1 2016 - Coverage of 10 Companies & Drug Profiles - Research and Markets
finance.yahoo.com - May 26 at 1:04 PM
theglobeandmail.com logoDon’t trade like I do’: Buy shares in Teck Resources instead
www.theglobeandmail.com - February 27 at 1:55 PM
finance.yahoo.com logoNeuroblastoma - Pipeline Review, H2 2015 - Research and Markets
finance.yahoo.com - January 28 at 2:01 PM

Social

Chart

MEI Pharma (MSHL) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by MarketBeat.com Staff